The Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease.
NurOwn is the clearest test yet of how far the agency may be willing to bend to approve a new medicine for a rare and deadly condition with few treatment options.
The meeting was scheduled after ALS advocates delivered a 30,000-signature petition seeking a public vetting of the treatment. "The amazing testimonials we have seen online do not align with the data that Brainstorm has shared," the group said in a statement. NurOwn is made from stem cells collected from patients' bone marrow. The cells are processed in a lab with biological proteins designed to promote nerve growth, and then injected into the spinal column.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
FDA skeptical of experimental ALS treatment pushed by patient advocatesThe Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease.
続きを読む »
FDA skeptical of experimental ALS treatment pushed by patient advocatesThe Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease.
続きを読む »
FDA skeptical of experimental ALS treatment pushed by patient advocatesThe Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease
続きを読む »
Some cold medicines might not work according to FDAThe drug is known as phenylephrine. It’s found in medicine you probably have at home, like Dayquil and Mucinex.
続きを読む »
Coherus BioSciences’ new injector treatment for cancer patients rejected by FDACoherus BioSciences said Monday that the U.S. Food and Drug Administration rejected its regulatory submission for a new on-body injector form of Udenyca, a...
続きを読む »
Latin American Heritage Festival in Birmingham celebrates music, food, cultureThe Saturday event at Birmingham Museum of Art was organized as part of National Hispanic Heritage Month.
続きを読む »